EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
← catalyst calendarNCT07262619 · readout ≤ 954 d
Sponsored by Eikon Therapeutics (industry) · EIKN — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
160estimated
Sites
10
Countries
Australia, New Zealand, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-20 | actual | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Solid Tumors
- MSI-H or dMMR Advanced Solid Tumors
- MSI-H/dMMR Gastric Cancer
- MSI-H/dMMR Colorectal Cancer
- MSI-H/dMMR Gastroesophageal-junction Cancer
- Endometrial Cancer
- Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
- Drug: EIK1005
- Drug: pembrolizumab (KEYTRUDA® )
Primary outcomes
what the primary-completion date above is the date OFDose-Limiting Toxicity (DLT) - Part 1
measured 21 Days
Adverse Events (AEs) - Part 1 and Part 2
measured From the time of first dose of study medication through 30 days following cessation of study treatment.
Permalink · EIKN's whole pipeline · Catalyst calendar · Every registered study · What changed